Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA

Journal of Ophthalmic Inflammation and Infection

Table 3 Study period ophthalmologic comorbidities and prior treatment for patients with non-infectious uveitis by treatment group

	CTS patients ^a (N = 4,568)	IMS patients ^b (N = 5,466)	BIO patients (N = 1,694)
Patient months	16,574	20,308	12,940
Mean months/treatment episode (time to discontinuation), mean (std)	3.63 (3.13)	3.72 (5.61)^a	7.64 (9.36)^a,b
Study period ophthalmologic comorbidities, mean (std)
Glaucoma	0.058 (0.22)	0.052 (0.22)^a	0.034 (0.14)^a
Cataract	0.022 (0.12)	0.025 (0.11)	0.016 (0.07)
Cystoid macular degeneration	0.013 (0.10)	0.010 (0.07)^a	0.005 (0.04)^a
Retinal detachments	0.011 (0.10)	0.004 (0.05)^a	0.002 (0.03)^a
Visual disturbances	0.007 (0.07)	0.004 (0.04)^a	0.003 (0.02)
Blindness	0.001 (0.03)	0.002 (0.03)	0.000 (0.01)
Other visual complications	0.011 (0.09)	0.015 (0.12)	0.007 (0.05)
Augmenting or switching
Augmented to immunosuppressants, N (%)	348 (7.60%)
Mean days to augmenting, conditional on augmenting, mean (std)	57 (56)
Augmented to biologics, N (%)	96 (2.10%)	346 (6.30%)
Mean days to augmenting, conditional on augmenting, mean (std)	42 (37)	78 (116)^a
Switched to immunosuppressants, N (%)	615 (13.50%)
Mean days to switching, conditional on switching, mean (std)	213 (299)
Switched to biologics, N (%)	221 (4.80%)	615 (11.30%)
Mean days to switching, conditional on switching, mean (std)	256 (358)	213 (295)

CTS, corticosteroids; IMS, immunosuppressive therapy; BIO, biologics. Chi-square tests were used to test differences in categorical variables. Wilcoxon tests were used to test differences in continuous variables. ^a,bData with superscripted letter(s) indicates a significant difference (P < 0.05) from the uveitis subtype represented by that letter.